Polydex Pharmaceuticals Stock Current Valuation
| POLXFDelisted Stock | USD 1.96 0.01 0.51% |
Valuation analysis of Polydex Pharmaceuticals helps investors to measure Polydex Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Polydex Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Polydex Pharmaceuticals is based on 3 months time horizon. Increasing Polydex Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Polydex pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Polydex Pharmaceuticals. Since Polydex Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Polydex Pink Sheet. However, Polydex Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.96 | Real 1.6 | Hype 1.96 | Naive 1.99 |
The real value of Polydex Pink Sheet, also known as its intrinsic value, is the underlying worth of Polydex Pharmaceuticals Company, which is reflected in its stock price. It is based on Polydex Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Polydex Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Polydex Pharmaceuticals helps investors to forecast how Polydex pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Polydex Pharmaceuticals more accurately as focusing exclusively on Polydex Pharmaceuticals' fundamentals will not take into account other important factors: Polydex Pharmaceuticals Company Current Valuation Analysis
Polydex Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Polydex Pharmaceuticals Current Valuation | 2.23 M |
Most of Polydex Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Polydex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Polydex Pharmaceuticals has a Current Valuation of 2.23 M. This is 99.98% lower than that of the Pharmaceuticals sector and 99.95% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Polydex Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Polydex Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Polydex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Polydex Pharmaceuticals by comparing valuation metrics of similar companies.Polydex Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Polydex Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.0824 | |||
| Profit Margin | (0.25) % | |||
| Operating Margin | (0.22) % | |||
| Current Valuation | 2.23 M | |||
| Shares Outstanding | 3.43 M | |||
| Number Of Shares Shorted | 11 | |||
| Price To Earning | 12.33 X | |||
| Price To Book | 0.42 X | |||
| Price To Sales | 0.51 X | |||
| Revenue | 4.05 M | |||
| Gross Profit | 970.3 K | |||
| EBITDA | (568.16 K) | |||
| Cash And Equivalents | 870.3 K | |||
| Cash Per Share | 0.25 X | |||
| Total Debt | 301.49 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 5.88 X | |||
| Book Value Per Share | 1.44 X | |||
| Cash Flow From Operations | (238.54 K) | |||
| Short Ratio | 0.02 X | |||
| Earnings Per Share | (0.13) X | |||
| Number Of Employees | 21 | |||
| Beta | 0.33 | |||
| Market Capitalization | 2.23 M | |||
| Total Asset | 6.56 M | |||
| Retained Earnings | (19.53 M) | |||
| Working Capital | 2.12 M | |||
| Current Asset | 3.41 M | |||
| Current Liabilities | 1.28 M | |||
| Z Score | 1.4 |
About Polydex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Polydex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Polydex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Polydex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Polydex Pink Sheet
If you are still planning to invest in Polydex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Polydex Pharmaceuticals' history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |